Mays Cancer Center at UT Health San Antonio melanoma expert Monte Shaheen, MD, was part of a team of investigators that conducted a phase II clinical trial to determine the efficacy and safety of administering the immunotherapy drug pembrolizumab before and after surgery in high-risk melanoma patients.